HIT Consultant July 17, 2024
Fred Pennic

What You Should Know:

Thyme Care, a leading value-based cancer care enabler raises $95M in funding capital led by Concord Health Partners, with participation from existing investors including CVS Health® Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Foresite Capital, and new investor SignalFire. The funding brings Thyme Care’s total funding to $178M.

– Thyme Care is a value-based cancer care enabler focused on improving patient outcomes and reducing healthcare costs. The new funding will fuel Thyme Care’s expansion into new markets, deepen existing partnerships, and enhance its clinical value-based care model.

Addressing the Cancer Care Crisis

The cancer care landscape is marked by escalating costs, fragmented care, and significant disparities in patient...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Investments, Payment Models, Trends, Value Based
How Houston Methodist’s ACO Reduced Its End-of-Life Spending by Nearly 20%
NPHI CEO Tom Koutsoumpas: Modernize Hospice Benefit for Value-Based Future
Policy Strategies To Propel Community Health Centers Into Value-Based Payment
Integrating Specialists for Success in Value-Based Care
CVS Health Sells MSSP Business to Wellvana

Share This Article